NCT03297424: A Study of PLX2853 in Advanced Malignancies

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Breast cancer patients are not eligible for the expansion phase
Exclusions: Patients with symptomatic or uncontrolled central nervous system or leptomeningeal metastases; Patients with prior exposure to a bromodomain (BET) inhibitor

Comments are closed.

Up ↑